Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice

Genome editing therapy for Duchenne muscular dystrophy (DMD) holds great promise, however, one major obstacle is delivery of the CRISPR-Cas9/sgRNA system to skeletal muscle tissues. In general, AAV vectors are used for in vivo delivery, but AAV injections cannot be repeated because of neutralization...

Descripción completa

Detalles Bibliográficos
Autores principales: Kenjo, Eriya, Hozumi, Hiroyuki, Makita, Yukimasa, Iwabuchi, Kumiko A., Fujimoto, Naoko, Matsumoto, Satoru, Kimura, Maya, Amano, Yuichiro, Ifuku, Masataka, Naoe, Youichi, Inukai, Naoto, Hotta, Akitsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654819/
https://www.ncbi.nlm.nih.gov/pubmed/34880218
http://dx.doi.org/10.1038/s41467-021-26714-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654819/
https://www.ncbi.nlm.nih.gov/pubmed/34880218
http://dx.doi.org/10.1038/s41467-021-26714-w

Ejemplares similares